Wells Fargo’s Autolus Therapeutics AUTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $340K | Buy |
212,592
+4,736
| +2% | +$7.43K | ﹤0.01% | 4871 |
|
|
2026
Q1 | $287K | Buy |
207,856
+10,773
| +5% | +$16.4K | ﹤0.01% | 4476 |
|
|
2025
Q4 | $392K | Sell |
197,083
-34,049
| -15% | -$52.3K | ﹤0.01% | 4655 |
|
|
2025
Q3 | $377K | Sell |
231,132
-21,970
| -9% | -$42.9K | ﹤0.01% | 4506 |
|
|
2025
Q2 | $577K | Sell |
253,102
-8,044
| -3% | -$13.3K | ﹤0.01% | 4035 |
|
|
2025
Q1 | $405K | Sell |
261,146
-5,169
| -2% | -$10.5K | ﹤0.01% | 4243 |
|
|
2024
Q4 | $626K | Sell |
266,315
-119,558
| -31% | -$404K | ﹤0.01% | 4035 |
|
|
2024
Q3 | $1.4M | Buy |
385,873
+5,567
| +1% | +$22.2K | ﹤0.01% | 3323 |
|
|
2024
Q2 | $1.32M | Buy |
380,306
+3,534
| +0.9% | +$15.3K | ﹤0.01% | 3297 |
|
|
2024
Q1 | $2.4M | Sell |
376,772
-30,678
| -8% | -$191K | ﹤0.01% | 2823 |
|
|
2023
Q4 | $2.62M | Sell |
407,450
-150,075
| -27% | -$572K | ﹤0.01% | 2691 |
|
|
2023
Q3 | $1.3M | Buy |
557,525
+38,083
| +7% | +$109K | ﹤0.01% | 3131 |
|
|
2023
Q2 | $1.24M | Buy |
519,442
+32,073
| +7% | +$76.1K | ﹤0.01% | 3307 |
|
|
2023
Q1 | $897K | Buy |
487,369
+111,708
| +30% | +$218K | ﹤0.01% | 3451 |
|
|
2022
Q4 | $714K | Sell |
375,661
-14,178
| -4% | -$35.9K | ﹤0.01% | 3432 |
|
|
2022
Q3 | $834K | Buy |
389,839
+25,884
| +7% | +$76.7K | ﹤0.01% | 3348 |
|
|
2022
Q2 | $1.03M | Buy |
363,955
+124,320
| +52% | +$378K | ﹤0.01% | 3275 |
|
|
2022
Q1 | $1M | Buy |
239,635
+40,462
| +20% | +$170K | ﹤0.01% | 3890 |
|
|
2021
Q4 | $1.03M | Sell |
199,173
-54,257
| -21% | -$326K | ﹤0.01% | 4077 |
|
|
2021
Q3 | $1.66M | Buy |
253,430
+110,426
| +77% | +$698K | ﹤0.01% | 3825 |
|
|
2021
Q2 | $950K | Buy |
143,004
+72,868
| +104% | +$452K | ﹤0.01% | 4242 |
|
|
2021
Q1 | $401K | Buy |
70,136
+43,361
| +162% | +$321K | ﹤0.01% | 4812 |
|
|
2020
Q4 | $239K | Buy |
26,775
+10,292
| +62% | +$110K | ﹤0.01% | 4986 |
|
|
2020
Q3 | $191K | Buy |
16,483
+4,007
| +32% | +$58.1K | ﹤0.01% | 4981 |
|
|
2020
Q2 | $200K | Sell |
12,476
-2,445
| -16% | -$27.1K | ﹤0.01% | 4910 |
|
|
2020
Q1 | $89K | Buy |
14,921
+13,119
| +728% | +$121K | ﹤0.01% | 5115 |
|
|
2019
Q4 | $24K | Sell |
1,802
-400
| -18% | -$5.24K | ﹤0.01% | 5702 |
|
|
2019
Q3 | $27K | Buy |
2,202
+1,502
| +215% | +$19.9K | ﹤0.01% | 5732 |
|
|
2019
Q2 | $11K | Buy |
700
+400
| +133% | +$8.95K | ﹤0.01% | 5895 |
|
|
2019
Q1 | $9K | Sell |
300
-250
| -45% | -$7.11K | ﹤0.01% | 5651 |
|
|
2018
Q4 | $18K | Sell |
550
-600
| -52% | -$19.7K | ﹤0.01% | 5799 |
|
|
2018
Q3 | $35K | Buy |
1,150
+900
| +360% | +$24.3K | ﹤0.01% | 5705 |
|
|
2018
Q2 | $7K | Buy |
+250
| New | +$6.61K | ﹤0.01% | 6022 |
|
Other funds holding AUTL
MCO
SP
AC
TAM
FLSM
LCM
Wells Fargo's AUTL Position: Q2 2026 in Review
Wells Fargo increased its Autolus Therapeutics (AUTL) stake by 2.3% in Q2 2026, buying an estimated $7.43K and bringing the position to 212,592 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #4871.
Wells Fargo first reported a position in AUTL in Q2 2018 and has held it in 33 quarters since. The position peaked at $2.62M in Q4 2023. 83 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.
- Wells Fargo held 212,592 shares of Autolus Therapeutics worth $340K as of Q2 2026.
- Wells Fargo bought 4,736 Autolus Therapeutics shares in Q2 2026, an estimated $7.43K.
- Autolus Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4871 holding.
- Wells Fargo first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 33 quarters since.
- Wells Fargo's Autolus Therapeutics position peaked at $2.62M in Q4 2023.
- 83 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.